Development of platforms for sorting, production, editing of beta cells
- Institution
- BROAD INSTITUTE, INC., MA
- Principal investigator
- Amit Choudhary
- Funding
- $652K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Patients suffering from type 1 diabetes must undergo burdensome, often lifelong, exogenous insulin dependence. Up to now, the only available replacement therapy is to transplant islets from cadaveric donors. However, such procedures present hurdles such as the scarcity of available donors and the rejection of transplanted cells by the patient’s immune system. Also, over time, the transplanted islets tend to die. Several types of stem cells, including embryonic stem cell and induced pluripotent stem cell, have been extensively studied to generate glucose-responsive insulin-secreting cells and represents a more tenable source of islets. However, a significant concern for transplantation therapy is the need for immunosuppressive drugs, which exhibit long term side effects and hinders the feasibility of this approach to the large population of T1D patients. Furthermore, cost-effective and large-scale production of these stem cell-derived beta cells is still a major challenge. We propose to apply chemical biology and genome engineering approaches to develop platforms for efficient sorting, production, and editing of these beta cells. PHS 398/2590 (Rev. 06/09) 1 Continuation Format Page
Research team
- Amit ChoudharyPI
- Neal Krishna DevarajPI
- Jeffrey Michael KarpPI
- Rohit N. KulkarniPI
LOADING MOONBASE SCORE
Questions for BROAD INSTITUTE, INC.
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Broad Institute, Inc.Not yet scored
Development of antimicrobials based on principles of induced proximity
Amit Choudhary · $481K · 2025–2027
- NIH · University of ChicagoNot yet scored
Role of Pancreatic Elastase in Beta Cell Health, Autoimmunity and Type 1 Diabetes
Mark S Anderson · $852K · 2025–2029
- NIH · Broad Institute, Inc.Not yet scored
Development of phosphorylation editing chimeras using kinase inhibitors
Amit Choudhary · $210K · 2024–2026